文献速递血脂与心血管预防冠心病

依洛尤单抗大幅降低LDL-C但脂蛋白(a)仍高者动脉壁炎症持续存在

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
PubMed 文献 · Eur Heart J · 2019-01-01

这项多中心随机双盲安慰剂对照研究纳入129例脂蛋白(a)升高患者,随机接受每月皮下依洛尤单抗420 mg或安慰剂。与安慰剂相比,依洛尤单抗使LDL-C降低60.7%、Lp(a)降低13.9%,但第16周指数血管最病变段靶本比(MDS TBR)变化无显著差异(-8.3% vs -5.3%,治疗差-3.0%,95%CI -7.4%至1.4%,P=0.18)。提示Lp(a)持续升高可能参与动脉壁炎症未改善。

要点

  • 依洛尤单抗使LDL-C降60.7%、Lp(a)仅降13.9%,Lp(a)仍处高位。
  • 第16周动脉壁炎症(MDS TBR)较安慰剂无显著改善(P=0.18)。
  • Lp(a)持续升高可能削弱降脂治疗对动脉壁炎症的获益。

核心结论

  • 在基线Lp(a)中位数200.0 nmol/L的患者中,依洛尤单抗大幅降低LDL-C、小幅降低Lp(a),动脉壁炎症未见显著改变。
  • Lp(a)持续升高可能参与动脉壁炎症未改善的机制。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照研究,纳入129例Lp(a)升高患者。
  • 受试者中位(IQR)年龄60.0(54.0-67.0)岁,Lp(a)中位数200.0(155.5-301.5)nmol/L[80.0(62.5-121.0)mg/dL]。
  • 随机接受每月皮下依洛尤单抗420 mg或安慰剂。
  • 主要评估指标为18F-氟脱氧葡萄糖PET/CT测定的指数血管(左颈动脉、右颈动脉或胸主动脉)最病变段靶本比(MDS TBR)。

主要发现

  • 与安慰剂相比,依洛尤单抗使LDL-C降低60.7%(95%CI 65.8-55.5),Lp(a)降低13.9%(95%CI 19.3-8.5)。
  • 依洛尤单抗组第16周平均(SD)LDL-C为1.6(0.7)mmol/L[60.1(28.1)mg/dL]。
  • 依洛尤单抗组第16周Lp(a)中位数(IQR)为188.0(140.0-268.0)nmol/L[75.2(56.0-107.2)mg/dL]。
  • 第16周指数血管MDS TBR变化:依洛尤单抗-8.3% vs 安慰剂-5.3%,治疗差-3.0%(95%CI -7.4%至1.4%),P=0.18。

临床怎么用

  • 对Lp(a)升高患者,依洛尤单抗可大幅降低LDL-C,但Lp(a)降幅有限且动脉壁炎症未显著改善。
  • 需关注Lp(a)持续升高对血管壁炎症和残余风险的影响,可能需要针对Lp(a)的额外干预策略。

局限性

  • 研究为16周短期随访,动脉壁炎症评估时间有限。
  • 依洛尤单抗对Lp(a)降幅仅13.9%,未能充分降低Lp(a)至正常水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Subjects with lipoprotein(a) [Lp(a)] elevation have increased arterial wall inflammation and cardiovascular risk. In patients at increased cardiovascular risk, arterial wall inflammation is reduced following lipid-lowering therapy by statin treatment or lipoprotein apheresis. However, it is unknown whether lipid-lowering treatment in elevated Lp(a) subjects alters arterial wall inflammation. We evaluated whether evolocumab, which lowers both low-density lipoprotein cholesterol (LDL-C) and Lp(a), attenuates arterial wall inflammation in patients with elevated Lp(a). METHODS AND RESULTS: In this multicentre, randomized, double-blind, placebo-controlled study, 129 patients {median [interquartile range (IQR)]: age 60.0 [54.0-67.0] years, Lp(a) 200.0 [155.5-301.5] nmol/L [80.0 (62.5-121.0) mg/dL]; mean [standard deviation (SD)] LDL-C 3.7 [1.0] mmol/L [144.0 (39.7) mg/dL]; National Cholesterol Education Program high risk, 25.6%} were randomized to monthly subcutaneous evolocumab 420 mg or placebo. Compared with placebo, evolocumab reduced LDL-C by 60.7% [95% confidence interval (CI) 65.8-55.5] and Lp(a) by 13.9% (95% CI 19.3-8.5). Among evolocumab-treated patients, the Week 16 mean (SD) LDL-C level was 1.6 (0.7) mmol/L [60.1 (28.1) mg/dL], and the median (IQR) Lp(a) level was 188.0 (140.0-268.0) nmol/L [75.2 (56.0-107.2) mg/dL]. Arterial wall inflammation [most diseased segment target-to-background ratio (MDS TBR)] in the index vessel (left carotid, right carotid, or thoracic aorta) was assessed by 18F-fluoro-deoxyglucose positron-emission tomography/computed tomography. Week 16 index vessel MDS TBR was not significantly altered with evolocumab (-8.3%) vs. placebo (-5.3%) [treatment difference -3.0% (95% CI -7.4% to 1.4%); P = 0.18]. CONCLUSION: Evolocumab treatment in patients with median baseline Lp(a) 200.0 nmol/L led to a large reduction in LDL-C and a small reduction in Lp(a), resulting in persistent elevated Lp(a) levels. The latter may have contributed to the unaltered arterial wall inflammation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Stiekema LCA, Stroes ESG, Verweij SL, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. 2019. PMID: 30561610. doi:10.1093/eurheartj/ehy862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。